You have 9 free searches left this month | for more free features.

City

Guangzhou (2)

Chengdu (1)

Condition

Hepatocellular Carcinoma (2)

Cholangiocarcinoma Non-resectable (1)

Soft Tissue Sarcoma (1)

Overall Status

Recruiting (2)

Not yet recruiting (1)

Withdrawn (1)

Sign in for free

Phase

phase 2 (4)

Sponsor

Shi Ming (2)

Second Affiliated Hospital, School of Medicine, Zhejiang University (1)

West China Hospital (1)

Collaborator

Intervention

candonilimab (4)

bevacizumab (2)

cisplatin (1)

gemcitabine (1)

Study Documents

Intervention Type

drug (4)

Funder Type

Other (4)

Study Type

Interventional (4)

candonilimab

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)

Withdrawn

Hepatocellular Carcinoma

Candonilimab
Bevacizumab

Guangzhou, Guangdong, China

Cancer Center Sun Yat-sen University

Jun 1, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)

Recruiting

Hepatocellular Carcinoma

Candonilimab
Bevacizumab

Guangzhou, Guangdong, China

Cancer Center Sun Yat-sen University

Feb 26, 2023

Soft Tissue Sarcoma Trial (Candonilimab)

Not yet recruiting

Soft Tissue Sarcoma

Candonilimab

(no location specified)

Jun 22, 2023

Cholangiocarcinoma Non-resectable Trial in Chengdu (Candonilimab, Cisplatin, Gemcitabine)

Recruiting

Cholangiocarcinoma Non-resectable

Candonilimab
+2 more

Chengdu, Sichuan, China

West China Hospital, Sichuan University

Aug 4, 2023